

Zelltherapie mit Granulozyten, Lymphozyten und Natürlichen Killerzellen

- (1) Arnold R, Pflieger H, Dietrich M, Heimpel H. The clinical efficacy of granulocyte transfusions: studies on the oral cavity. *Blut*. 1977; 35: 405-414.
- (2) Rutella S, Pierelli L, Sica S et al. Efficacy of granulocyte transfusions for neutropenia-related infections: retrospective analysis of predictive factors. *Cytotherapy*. 2003; 5: 19-30.
- (3) Liles WC, Huang JE, Llewellyn C et al. A comparative trial of granulocyte-colony-stimulating factor and dexamethasone, separately and in combination, for the mobilization of neutrophils in the peripheral blood of normal volunteers. *Transfusion*. 1997; 37: 182-187.
- (4) Heuft HG, Goudeva L, Sel S, Blasczyk R. Equivalent mobilization and collection of granulocytes for transfusion after administration of glycosylated G-CSF (3 microg/kg) plus dexamethasone versus glycosylated G-CSF (12 microg/kg) alone. *Transfusion*. 2002; 42: 928-934.
- (5) Lee JH, Leitman SF, Klein HG. A controlled comparison of the efficacy of hetastarch and pentastarch in granulocyte collections by centrifugal leukapheresis. *Blood*. 1995; 86: 4662-4666.
- (6) Wissenschaftlicher Beirat der Bundesärztekammer. Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie). www.baek.de. 2005.
- (7) Bux J, Einsele H. Granulozytenkonzentrate. In: Bundesärztekammer, ed. Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. Köln: Deutscher Ärzte-Verlag; 2003: 51-61.
- (8) Council of Europe. Council of Europe Guide to the Preparation, Use and Quality Assurance of Blood Components. 9th edition. 2005. Strasbourg, France, Council of Europe Publishing.
- (9) Worel N, Kurz M, Peters C, Hocker P. Serial granulocytapheresis under daily administration of rHuG-CSF: effects on peripheral blood counts, collection efficiency, and yield. *Transfusion*. 2001; 41: 390-395.
- (10) von Laer D, Serr A, Meyer-König U et al. Human cytomegalovirus immediate early and late transcripts are expressed in all major leukocyte populations in vivo. *J Infect Dis*. 1995; 172: 365-370.
- (11) Nichols WG, Price T, Boeckh M. Donor serostatus and CMV infection and disease among recipients of prophylactic granulocyte transfusions. *Blood*. 2003; 101: 5091-5092.
- (12) Vij R, DiPersio JF, Venkatraman P et al. Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation. *Blood*. 2003; 101: 2067-2069.
- (13) Lightfoot T, Gallelli J, Matsuo K et al. Evaluation of solutions for the storage of granulocyte colony-stimulating factor-mobilized granulocyte concentrates. *Vox Sang*. 2001; 80: 106-111.
- (14) Schmitt A, Reinhardt P, Schmitt M et al. Functional State of steroid- versus G-CSF-mobilized granulocytes: Considerations about the storage of granulocyte concentrates for neutropenic patients. *Infusionsther Transfusionsmed*. 2002; 29: 57-64.
- (15) Lightfoot T, Leitman SF, Stroncek DF. Storage of G-CSF-mobilized granulocyte concentrates. *Transfusion*. 2000; 40: 1104-1110.
- (16) McCullough J, Weiblen BJ, Fine D. Effects of storage of granulocytes on their fate in vivo. *Transfusion*. 1983; 23: 20-24.
- (17) Lane TA, Lamkin GE. Adherence of fresh and stored granulocytes to endothelial cells. Effect of storage temperature. *Transfusion*. 1988; 28: 237-242.
- (18) Bux J, Cassens U, Dielschneider T et al. Tolerance of granulocyte donors towards granulocyte colony-stimulating factor stimulation and of patients towards granulocyte transfusions: results of a multicentre study. *Vox Sang*. 2003; 85: 322-325.
- (19) Wiesneth M, Burkhart J, Meyer T, Schrezenmeier H. Hämatopoietische Stammzelltransplantationen: Gewinnung, Präparation, klinischer Einsatz. *Hämotherapie*. 2004; 3: 16-34.



- (20) Wright DG, Robichaud KJ, Pizzo PA, Deisseroth AB. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. *N Engl J Med.* 1981; 304: 1185-1189.
- (21) Dale DC, Liles WC, Summer WR, Nelson S. Review: granulocyte colony-stimulating factor-role and relationships in infectious diseases. *J Infect Dis.* 1995; 172: 1061-1075.
- (22) Jilma B, Hergovich N, Homoncik M et al. Rapid down modulation of P-selectin glycoprotein ligand-1 (PSGL-1, CD162) by G-CSF in humans. *Transfusion.* 2002; 42: 328-333.
- (23) Stroncek DF, Leonard K, Eiber G et al. Alloimmunization after granulocyte transfusions. *Transfusion.* 1996; 36: 1009-1015.
- (24) Price TH, Bowden RA, Boeckh M et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. *Blood* 2000 Jun 1; 95(11): 3302-9. 95: 3302-3309.
- (25) Cesaro S, Chinello P, De Silvestro G et al. Granulocyte transfusions from G-CSF-stimulated donors for the treatment of severe infections in neutropenic pediatric patients with onco-hematological diseases. *Support Care Cancer.* 2003; 11: 101-106.
- (26) Lee JJ, Chung IJ, Park MR et al. Clinical efficacy of granulocyte transfusion therapy in patients with neutropenia-related infections. *Leukemia.* 2001; 15: 203-207.
- (27) Stanworth S, Massey E, Hyde C et al. Granulocyte transfusions for treating infections in patients with neutropenia or neutrophil dysfunction. *Cochrane Database Syst Rev.* 2005; CD005339.
- (28) Mohan P, Brocklehurst P. Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropaenia. *Cochrane Database Syst Rev.* 2003; CD003956.
- (29) Singer MS, Seibel NL, Vezina G, Choi SS, Dinndorf PA. Successful treatment of invasive aspergillosis in two patients with acute myelogenous leukemia. *J Pediatr Hematol Oncol.* 2003; 25: 252-256.
- (30) Grigull L, Schrauder A, Schmitt-Thomssen A, Sykora K, Welte K. Efficacy and safety of G-CSF mobilized granulocyte transfusions in four neutropenic children with sepsis and invasive fungal infection. *Infection.* 2002; 30: 267-271.
- (31) Cairo MS, Worcester CC, Rucker RW et al. Randomized trial of granulocyte transfusions versus intravenous immune globulin therapy for neonatal neutropenia and sepsis. *J Pediatr.* 1992; 120: 281-285.
- (32) Hubel K, Carter RA, Liles WC et al. Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. *Transfusion.* 2002; 42: 1414-1421.
- (33) Kerr JP, Liakopolou E, Brown J et al. The use of stimulated granulocyte transfusions to prevent recurrence of past severe infections after allogeneic stem cell transplantation. *Br J Haematol.* 2003; 123: 114-118.
- (34) von Planta M, Ozsahin H, Schrotten H, Stauffer UG, Seger RA. Greater omentum flaps and granulocyte transfusions as combined therapy of liver abscess in chronic granulomatous disease. *Eur J Pediatr Surg.* 1997; 7: 234-236.
- (35) Lee JJ, Song HC, Chung IJ et al. Clinical efficacy and prediction of response to granulocyte transfusion therapy for patients with neutropenia-related infections. *Haematologica.* 2004; 89: 632-633.
- (36) Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. *Blood.* 1990; 76: 2462-2465.
- (37) Kolb HJ, Schmid C, Weisser M et al. Cytoreduction, DLL, or mobilized peripheral blood progenitors. *Ann Hematol.* 2002; 81 Suppl 2: S30-S33.
- (38) Slavin S, Morecki S, Weiss L, Or R. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation. *J Hematother Stem Cell Res.* 2002; 11: 265-276.





- (39) Feinstein L, Sandmaier B, Maloney D et al. Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. *Ann N Y Acad Sci.* 2001; 938: 328-337.
- (40) Bacigalupo A, Palandri F. Management of acute graft versus host disease (GvHD). *Hematol J.* 2004; 5: 189-196.
- (41) Michallet AS, Nicolini F, Furst S et al. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). *Bone Marrow Transplant.* 2005; 35: 601-608.
- (42) Peggs KS, Thomson K, Hart DP et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. *Blood.* 2004; 103: 1548-1556.
- (43) Wiesneth M, Schreiner T, Friedrich W et al. Combined CD34 positive plus CD2 negative selection for effective T-cell depletion as GvHD-prophylaxis in HLA-nonidentical blood progenitor cell transplantation. *Transfus Sci.* 1996; 17: 629-635.
- (44) Gilleece MH, Dazzi F. Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia. *Leuk Lymphoma.* 2003; 44: 23-28.
- (45) Zeiser R, Bertz H, Spyridonidis A, Houet L, Finke J. Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives. *Bone Marrow Transplant.* 2004; 34: 923-928.
- (46) Massenkeil G, Roigas J, Nagy M et al. Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity. *Bone Marrow Transplant.* 2004; 34: 309-316.
- (47) Bishop MR, Fowler DH, Marchigiani D et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. *J Clin Oncol.* 2004; 22: 3886-3892.
- (48) Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. *J Clin Oncol.* 2005; 23: 5675-5687.
- (49) Teichmann JV, Ludwig WD, Thiel E. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor. *Leuk Res* 1992;16(3):287-98
- (50) Pawelec G: MHC-unrestricted immune surveillance of leukemia. *Cancer Biother* 1994; 9(3): 265-288.
- (51) Storkus WJ, Dawson JR: Target structures involved in natural killing (NK): characteristics, distribution, and candidate molecules. *Crit Rev Immunol* 1991; 10(5): 393-416.
- (52) Smyth MJ, Hayakawa Y, Takeda K, Yagita H: New aspects of natural-killer-cell surveillance and therapy of cancer. *Nat Rev Cancer* 2002; 2(11): 850-861.
- (53) Chumbley G, King A, Robertson K, Holmes N, Loke YW: Resistance of HLA-G and HLA-A2 transfectants to lysis by decidual NK cells. *Cell Immunol* 1994; 155(2): 312-322
- (54) Mandelboim O, Pazmany L, Davis DM, Vales-Gomez M, Reyburn HT, Rybalov B, Strominger JL: Multiple receptors for HLA-G on human natural killer cells. *Proc Natl Acad Sci U S A* 1997; 94(26): 14666-14670.
- (55) Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. *Science* 2002; 295(5562): 2097-100.
- (56) Uharek L, Zeis M, Glass B, Steinmann J, Dreger P, Gassmann W, Schmitz N, Muller-Ruchholtz W: High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2. *Leukemia* 1996; 10: 1758-1764.
- (57) Son YI, Dallal RM, Mailliard RB, Egawa S, Jonak ZL, Lotze MT: Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells. *Cancer Res* 2001; 61(3): 884-888.





- (58) Koehl U, Sorensen J, Esser R, Zimmermann S, Gruttner HP, Tonn T, Seidl C, Seifried E, Klingebiel T, Schwabe D: IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. *Blood Cells Mol Dis*. 2004; 33(3): 261-266.
- (59) Benyunes MC, Massumoto C, York A, Higuchi CM, Buckner CD, Thompson JA, Petersen FB, Fefer A: Interleukin-2 with or without lymphokine-activated killer cell as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. *Bone Marrow Transplant* 1993; 12(2): 159-163.
- (60) Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, Pierz DM, Chen DK, Budzilovich GN, Ransohoff J: Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. *Cancer* 1995; 76(5): 840-852.
- (61) Fujimiya Y, Suzuki Y, Katakura R, Ohno T: Injury to autologous normal tissues and tumors mediated by lymphokine-activated killer (LAK) cells generated in vitro from peripheral blood mononuclear cells of glioblastoma patients. *J Hematother* 1999; 8(1): 29-37.
- (62) Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebbersold P, Leitman S, Linehan WM, Seipp CA: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. *J Natl Cancer Inst* 1993; 85(8): 622-632.
- (63) Kimoto Y, Tanaka T, Tanji Y, Fujiwara A, Taguchi T: Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies. *Biotherapy* 1994; 8(1): 41-50
- (64) Nagayama H, Takahashi S, Takahashi T, Ogami K, Ikebuchi K, To Tani K, Asano S: IL-2/LAK therapy for refractory acute monoblastic leukemia relapsing after unrelated allogeneic bone marrow transplantation. *Bone Marrow Transplant* 1999; 23(2): 183-185
- (65) Whiteside TL, Vujanovic NL, Herberman RB: Natural killer cells and tumor therapy. *Curr Top Microbiol Immunol* 1998; 230: 221-244.
- (66) Gong JH, Maki G, Klingemann HG: Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. *Leukemia* 1994; 8: 652-658
- (67) Yan Y, Steinherz P, Klingemann HG, Dennig D, Childs BH, McGuirk J, O'Reilly RJ: Antileukemia activity of a natural killer cell line against human leukemia. *Clin Cancer Res* 1998; 4: 2859-2868.
- (67) Drexler HG and Matsuo Y: Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma. *Leukemia* 2000; 14: 777-782.
- (68) Tonn T, Becker S, Esser R, Schwabe D, Seifried E: Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. *J Hematother Stem Cell Res* 2001; 10(4): 535-544.
- (69) Uherek C, Groner B, Wels W: Chimeric antigen receptors for the retargeting of cytotoxic effector cells. *J Hematother Stem Cell Res* 2001; 10: 523-534.
- (70) Wiesneth M, Hertenstein B, Bunjes D, Schmeiser T, Arnold R, Heimpel H, Heit W: T-cell depletion versus methotrexate as GvHD-prophylaxis in allogeneic bone marrow transplantation for leukaemia. *Eur J Haematol* 1988; 41: 243-249.